Tuesday, March 21, 2023
Clinical Advances in
Read Overview
Eosinophilic gastrointestinal diseases (EGIDs) comprise a group of disorders of the gastrointestinal tract marked by an increase in tissue eosinophils in the absence of other eosinophil-promoting diseases, such as infections, cancer, or inflammatory bowel disease (IBD). With the increased availability of endoscopy, EGIDs are being diagnosed more frequently than ever before, although there are still often lengthy diagnostic delays. At the same time, gains in knowledge about the underlying pathophysiology of EGIDs have led to accelerated research into new treatments, including biologic agents that target specific cell types and cytokines implicated in EGID pathogenesis. This Clinical Advances encompasses an array of CME-accredited video- and text-based educational programs presented by leading experts that examine the latest state of knowledge on the pathogenesis, diagnosis, and clinical management of EGIDs.
Supported by an independent educational grant from Allakos
Steering Committee Member Chair
Professor of Medicine
Division of Gastroenterology and Hepatology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Professor or Medicine
Division of Allergy, Immunology
University of California San Diego
San Diego, California
Professor of Medicine
Director, GI Physiology Laboratory
Co-Director, Michigan Bowel Control Program
University of Michigan
Ann Arbor, Michigan
Professor of Medicine
Feinberg School or Medicine
Northwestern University
Chicago, Illinois
Staff Pathologist
Division of Pathology and Laboratory Medicine
Cincinnati Childrenâs Hospital Medical Center
Professor of Pathology
University of Cincinnati Departments of Pathology, Laboratory Medicine, and Pediatrics
University of Cincinnati College of Medicine
Cincinnati, Ohio
Associate Professor of Gastroenterology
University of Utah Health
Salt Lake City, Utah
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Adare; Aimmune; Allakos; Alimentiv; Amgen; Arena; AstraZeneca; Biorasi; Bristol Myers Squibb; Calypso; Celgene; Celldex; Eli Lilly; EsoCap; GlaxoSmithKline; Gossamer Bio; Parexel; Receptos; Regeneron; Robarts; Salix; Sanofi; Shire; Takeda
Received grants for clinical research from: Adare; Allakos; AstraZeneca; Celgene; GlaxoSmithKline; Meritage; Miraca; Nutricia; Receptos; Regeneron; Shire; Takeda
Other: Allakos; Banner; Holoclara
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; AImmune; DBV; Regeneron
Other: co-inventor of oral viscous budesonide, UCSD patent, licensed by Takeda-Shire
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie; Allakos; Arena; Alnylam; Biomerica; Cosmo; IM Health; Ironwood; Phathom; Redhill; Salix; Takeda; Urovant; Vibrant
Received grants for clinical research from: Biomerica; Commonwealth Diagnostic International; QOL Medical; Salix; Vibrant
Owns stock, stock options, or bonds from: GI on Demand; Modify Health; Ritter
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allakos; AstraZeneca; Nutricia; Regeneron; Sanofi
Has disclosed the following relevant financial relationships:
Received grants for clinical research from: Receptos; Regeneron; Shire
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alladapt, Allakos; AstraZeneca; Ellodi; Eli Lilly; Sanofi; Takeda
Served as a speaker or a member of a speakers bureau for: Regeneron
Received grants for clinical research from: Allakos; Chobani
Owns stock, stock options, or bonds from: Nexeos
